• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5080760)   Today's Articles (355)
For: Pfaller MA, Jones RN, Biedenbach DJ. Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). Diagn Microbiol Infect Dis 2001;41:177-82. [PMID: 11777656 DOI: 10.1016/s0732-8893(01)00319-4] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Number Cited by Other Article(s)
1
Pettit RS, Neu N, Cies JJ, Lapin C, Muhlebach MS, Novak KJ, Nguyen ST, Saiman L, Nicolau DP, Kuti JL. Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis. J Antimicrob Chemother 2015;71:189-95. [PMID: 26416780 DOI: 10.1093/jac/dkv289] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2015] [Accepted: 08/17/2015] [Indexed: 01/10/2023]  Open
2
Biswal I, Arora BS, Kasana D, Neetushree. Incidence of multidrug resistant pseudomonas aeruginosa isolated from burn patients and environment of teaching institution. J Clin Diagn Res 2014;8:DC26-9. [PMID: 24995179 DOI: 10.7860/jcdr/2014/7483.4383] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2013] [Accepted: 03/03/2014] [Indexed: 11/24/2022]
3
Colardyn F. APPROPRIATE AND TIMELY EMPIRICAL ANTIMICROBIAL TREATMENT OF ICU INFECTIONS - A ROLE FOR CARBAPENEMS. Acta Clin Belg 2014;60:51-62. [PMID: 16082989 DOI: 10.1179/acb.2005.011] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
4
Rhomberg PR, Jones RN. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis 2010;65:414-26. [PMID: 19833471 DOI: 10.1016/j.diagmicrobio.2009.08.020] [Citation(s) in RCA: 136] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2009] [Accepted: 08/28/2009] [Indexed: 10/20/2022]
5
Isturiz R. Global resistance trends and the potential impact on empirical therapy. Int J Antimicrob Agents 2009;32 Suppl 4:S201-6. [PMID: 19134520 DOI: 10.1016/s0924-8579(09)70003-2] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
6
Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance. Diagn Microbiol Infect Dis 2008;61:203-13. [DOI: 10.1016/j.diagmicrobio.2008.01.017] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2008] [Revised: 01/16/2008] [Accepted: 01/17/2008] [Indexed: 11/18/2022]
7
Rhomberg PR, Deshpande LM, Kirby JT, Jones RN. Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006). Diagn Microbiol Infect Dis 2007;59:425-32. [PMID: 17662557 DOI: 10.1016/j.diagmicrobio.2007.05.009] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2007] [Accepted: 05/18/2007] [Indexed: 11/24/2022]
8
Bulitta JB, Duffull SB, Kinzig-Schippers M, Holzgrabe U, Stephan U, Drusano GL, Sörgel F. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 2007;51:2497-507. [PMID: 17485505 PMCID: PMC1913222 DOI: 10.1128/aac.01477-06] [Citation(s) in RCA: 105] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2006] [Revised: 02/11/2007] [Accepted: 04/27/2007] [Indexed: 11/20/2022]  Open
9
Bayram A, Balci I. Patterns of antimicrobial resistance in a surgical intensive care unit of a university hospital in Turkey. BMC Infect Dis 2006;6:155. [PMID: 17064415 PMCID: PMC1633736 DOI: 10.1186/1471-2334-6-155] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2006] [Accepted: 10/25/2006] [Indexed: 11/12/2022]  Open
10
Rhomberg PR, Jones RN. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Diagn Microbiol Infect Dis 2006;57:207-15. [PMID: 16949243 DOI: 10.1016/j.diagmicrobio.2006.07.009] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2006] [Accepted: 07/14/2006] [Indexed: 11/24/2022]
11
Jones RN, Sader HS, Fritsche TR, Rhomberg PR. Carbapenem susceptibility discords among Acinetobacter isolates. Clin Infect Dis 2006;42:158. [PMID: 16323113 DOI: 10.1086/498754] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]  Open
12
Unal S, Garcia-Rodriguez JA. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004. Diagn Microbiol Infect Dis 2006;53:265-71. [PMID: 16360550 DOI: 10.1016/j.diagmicrobio.2005.10.002] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2005] [Accepted: 10/16/2005] [Indexed: 02/06/2023]
13
Jones RN, Mendes C, Turner PJ, Masterton R. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004. Diagn Microbiol Infect Dis 2006;53:247-56. [PMID: 16360548 DOI: 10.1016/j.diagmicrobio.2005.10.006] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2005] [Accepted: 10/16/2005] [Indexed: 12/29/2022]
14
Rhomberg PR, Fritsche TR, Sader HS, Jones RN. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA). Diagn Microbiol Infect Dis 2006;56:57-62. [PMID: 16631338 DOI: 10.1016/j.diagmicrobio.2005.12.009] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2005] [Accepted: 12/15/2005] [Indexed: 11/30/2022]
15
Ramphal R, Ambrose PG. Extended-Spectrum β-Lactamases and Clinical Outcomes: Current Data. Clin Infect Dis 2006;42 Suppl 4:S164-72. [PMID: 16544267 DOI: 10.1086/500663] [Citation(s) in RCA: 175] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]  Open
16
Rhomberg PR, Fritsche TR, Sader HS, Jones RN. Clonal occurrences of multidrug-resistant Gram-negative bacilli: report from the Meropenem Yearly Susceptibility Test Information Collection Surveillance Program in the United States (2004). Diagn Microbiol Infect Dis 2006;54:249-57. [PMID: 16466890 DOI: 10.1016/j.diagmicrobio.2005.10.010] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2005] [Accepted: 10/21/2005] [Indexed: 11/28/2022]
17
Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 2005;11 Suppl 4:17-32. [PMID: 15953020 DOI: 10.1111/j.1469-0691.2005.01161.x] [Citation(s) in RCA: 221] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
18
Fish DN, Teitelbaum I, Abraham E. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2005;49:2421-8. [PMID: 15917542 PMCID: PMC1140495 DOI: 10.1128/aac.49.6.2421-2428.2005] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
19
Müller J, Garami M, Constantin T, Schmidt M, Fekete G, Kovács G. Meropenem in the treatment of febrile neutropenic children. Pediatr Hematol Oncol 2005;22:277-84. [PMID: 16020114 DOI: 10.1080/08880010590935167] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
20
Karlowsky JA, Jones ME, Thornsberry C, Evangelista AT, Yee YC, Sahm DF. Stable Antimicrobial Susceptibility Rates for Clinical Isolates of Pseudomonas aeruginosa from the 2001–2003 Tracking Resistance in the United States Today Surveillance Studies. Clin Infect Dis 2005;40 Suppl 2:S89-98. [PMID: 15712102 DOI: 10.1086/426188] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]  Open
21
Obritsch MD, Fish DN, MacLaren R, Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother 2005;48:4606-10. [PMID: 15561832 PMCID: PMC529178 DOI: 10.1128/aac.48.12.4606-4610.2004] [Citation(s) in RCA: 204] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]  Open
22
Novelli A, Adembri C, Livi P, Fallani S, Mazzei T, De Gaudio AR. Pharmacokinetic Evaluation of Meropenem and Imipenem in Critically Ill Patients with Sepsis. Clin Pharmacokinet 2005;44:539-49. [PMID: 15871639 DOI: 10.2165/00003088-200544050-00007] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
23
Tognim MCB, Andrade SS, Silbert S, Gales AC, Jones RN, Sader HS. Resistance trends of Acinetobacter spp. in Latin America and characterization of international dissemination of multi-drug resistant strains: five-year report of the SENTRY Antimicrobial Surveillance Program. Int J Infect Dis 2004;8:284-91. [PMID: 15325597 DOI: 10.1016/j.ijid.2003.11.009] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2003] [Revised: 11/10/2003] [Accepted: 11/11/2003] [Indexed: 02/06/2023]  Open
24
Rhomberg PR, Jones RN, Sader HS, Fritsche TR. Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003). Diagn Microbiol Infect Dis 2004;49:273-81. [PMID: 15313533 DOI: 10.1016/j.diagmicrobio.2004.02.003] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2003] [Accepted: 02/10/2004] [Indexed: 10/26/2022]
25
Flamm RK, Weaver MK, Thornsberry C, Jones ME, Karlowsky JA, Sahm DF. Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002. Antimicrob Agents Chemother 2004;48:2431-6. [PMID: 15215091 PMCID: PMC434174 DOI: 10.1128/aac.48.7.2431-2436.2004] [Citation(s) in RCA: 86] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
26
Critchley IA, Karlowsky JA. Optimal use of antibiotic resistance surveillance systems. Clin Microbiol Infect 2004;10:502-11. [PMID: 15191377 DOI: 10.1111/j.1469-0691.2004.00911.x] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
27
Jones RN, Deshpande L, Fritsche TR, Sader HS. Determination of epidemic clonality among multidrug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999–2003). Diagn Microbiol Infect Dis 2004;49:211-6. [PMID: 15246512 DOI: 10.1016/j.diagmicrobio.2004.03.016] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2004] [Accepted: 03/22/2004] [Indexed: 11/24/2022]
28
Jung R, Fish DN, Obritsch MD, MacLaren R. Surveillance of multi-drug resistant Pseudomonas aeruginosa in an urban tertiary-care teaching hospital. J Hosp Infect 2004;57:105-11. [PMID: 15183239 DOI: 10.1016/j.jhin.2004.03.001] [Citation(s) in RCA: 78] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2003] [Accepted: 03/01/2004] [Indexed: 11/25/2022]
29
Toraman ZA, Yakupogullari Y, Kizirgil A. Detection of metallo β-lactamase production and antibiotic resistance with E-test method in pseudomonas, acinetobacter and klebsiella strains, in Turkey. J Infect Chemother 2004;10:257-61. [PMID: 16163458 DOI: 10.1007/s10156-004-0333-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2004] [Accepted: 07/12/2004] [Indexed: 10/26/2022]
30
Kuti JL, Florea NR, Nightingale CH, Nicolau DP. Pharmacodynamics of Meropenem and Imipenem Against Enterobacteriaceae,Acinetobacter baumannii, andPseudomonas aeruginosa. Pharmacotherapy 2004;24:8-15. [PMID: 14740783 DOI: 10.1592/phco.24.1.8.34804] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
31
Rhomberg PR, Jones RN. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America. Diagn Microbiol Infect Dis 2003;47:365-72. [PMID: 12967752 DOI: 10.1016/s0732-8893(03)00112-3] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
32
Friedland I, Stinson L, Ikaiddi M, Harm S, Woods GL. Resistance in Enterobacteriaceae: results of a multicenter surveillance study, 1995-2000. Infect Control Hosp Epidemiol 2003;24:607-12. [PMID: 12940583 DOI: 10.1086/502252] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
33
Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 2003;47:1681-8. [PMID: 12709340 PMCID: PMC153334 DOI: 10.1128/aac.47.5.1681-1688.2003] [Citation(s) in RCA: 217] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
34
Friedland I, Stinson L, Ikaiddi M, Harm S, Woods GL. Phenotypic antimicrobial resistance patterns in Pseudomonas aeruginosa and Acinetobacter: results of a Multicenter Intensive Care Unit Surveillance Study, 1995-2000. Diagn Microbiol Infect Dis 2003;45:245-50. [PMID: 12729994 DOI: 10.1016/s0732-8893(02)00503-5] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
35
MYSTIC: closing summary. Diagn Microbiol Infect Dis 2001. [DOI: 10.1016/s0732-8893(01)00322-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA